Palvella Therapeutics, Inc. (PVLA) vs Recursion Pharmaceuticals, Inc. (RXRX)

Palvella Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Palvella Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.1B and $2.1B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 142.9% against −15.1%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −945.9%) and the higher return on invested capital (0.00% vs −92.2%). Across the 18 metrics below, Palvella Therapeutics, Inc. leads on 13 and Recursion Pharmaceuticals, Inc. on 5.

Valuation

Metric PVLA RXRX Biotechnology median
P/E n/m n/m 7.88
P/S 48.46 36.30 11.47
P/B 9.15 2.18 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 42.37 26.34 10.73
Earnings yield (3.50%) (27.81%) (28.84%)
Free cash flow yield (1.62%) (17.79%) (23.03%)

Profitability

Metric PVLA RXRX Biotechnology median
Gross margin 100.00% 3.48% 65.16%
Operating margin 0.00% (991.72%) 0.00%
Net margin 0.00% (945.92%) 0.00%
Free cash flow margin 0.00% (645.82%) 0.00%
Return on equity (46.63%) (56.58%) (57.72%)
Return on assets (37.70%) (41.26%) (49.22%)
Return on invested capital 0.00% (92.22%) 0.00%

Growth

Metric PVLA RXRX Biotechnology median
Revenue growth (TTM) 142.89% (15.08%) 5.64%
EPS growth (last fiscal year) 52.62% 14.79% —
Revenue growth, 5-year CAGR 8.03% 48.97% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PVLA RXRX Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 21.18 5.03 4.73
Net debt to EBITDA 1.50 1.31 0.96

Dividend

Metric PVLA RXRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PVLA RXRX Biotechnology median
Market cap 2.10b 2.11b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack